Monoclonal antibodies against macrophage colony-stimulating factor diminish the number of circulating intermediate and nonclassical (CD14(++)CD16(+)/CD14(+)CD16(++)) monocytes in rheumatoid arthritis patient.
Mariusz
M
Korkosz
Karolina
K
Bukowska-Strakova
Seth
S
Sadis
Tomasz
T
Grodzicki
Maciej
M
Siedlar
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000276:immunology; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy / Q000276:immunology; D004311:Double-Blind Method; D005260:Female; D058851:GPI-Linked Proteins / Q000097:blood / Q000276:immunology; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000097:blood* / Q000276:immunology; D016173:Macrophage Colony-Stimulating Factor / Q000037:antagonists & inhibitors* / Q000097:blood / Q000276:immunology; D008297:Male; D009000:Monocytes / Q000276:immunology / Q000378:metabolism*; D017452:Receptors, IgG / Q000097:blood* / Q000276:immunology
D000911:Antibodies, Monoclonal; C428200:FCGR3B protein, human; D058851:GPI-Linked Proteins; D018950:Lipopolysaccharide Receptors; D017452:Receptors, IgG; D016173:Macrophage Colony-Stimulating Factor